BRPI1012128A2 - composições contendo berberina ou seus análogos para tratamento de rosácea ou distúrbios de pele relacionados com face vermelha. - Google Patents

composições contendo berberina ou seus análogos para tratamento de rosácea ou distúrbios de pele relacionados com face vermelha.

Info

Publication number
BRPI1012128A2
BRPI1012128A2 BRPI1012128A BRPI1012128A BRPI1012128A2 BR PI1012128 A2 BRPI1012128 A2 BR PI1012128A2 BR PI1012128 A BRPI1012128 A BR PI1012128A BR PI1012128 A BRPI1012128 A BR PI1012128A BR PI1012128 A2 BRPI1012128 A2 BR PI1012128A2
Authority
BR
Brazil
Prior art keywords
rosacea
analogues
red
treatment
compositions containing
Prior art date
Application number
BRPI1012128A
Other languages
English (en)
Inventor
Shuen-Lu Huang
Tse-Wen Chang
Weng-Hung Chung
Original Assignee
Derman Biomedicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Derman Biomedicine Co Ltd filed Critical Derman Biomedicine Co Ltd
Publication of BRPI1012128A2 publication Critical patent/BRPI1012128A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
BRPI1012128A 2009-06-30 2010-06-30 composições contendo berberina ou seus análogos para tratamento de rosácea ou distúrbios de pele relacionados com face vermelha. BRPI1012128A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22172509P 2009-06-30 2009-06-30
PCT/CN2010/000983 WO2011000218A1 (en) 2009-06-30 2010-06-30 Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders

Publications (1)

Publication Number Publication Date
BRPI1012128A2 true BRPI1012128A2 (pt) 2016-03-29

Family

ID=43410481

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012128A BRPI1012128A2 (pt) 2009-06-30 2010-06-30 composições contendo berberina ou seus análogos para tratamento de rosácea ou distúrbios de pele relacionados com face vermelha.

Country Status (16)

Country Link
US (1) US9486402B2 (pt)
EP (1) EP2448577B1 (pt)
JP (2) JP6159084B2 (pt)
KR (3) KR101699572B1 (pt)
CN (2) CN102481290A (pt)
AU (1) AU2010268647B2 (pt)
BR (1) BRPI1012128A2 (pt)
CA (1) CA2766834C (pt)
ES (1) ES2600909T3 (pt)
HK (1) HK1224206A1 (pt)
IL (1) IL217264A (pt)
MX (1) MX344787B (pt)
NZ (1) NZ597645A (pt)
PL (1) PL2448577T3 (pt)
RU (2) RU2533458C2 (pt)
WO (1) WO2011000218A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201538156A (zh) * 2013-12-19 2015-10-16 Twi Biotechnology Inc 小蘗鹼配方及其用途
US20160263092A1 (en) 2013-12-19 2016-09-15 Twi Biotechnology, Inc. Therapeutic uses of berberine formulations
WO2016210230A1 (en) * 2015-06-24 2016-12-29 Twi Biotechnology, Inc. Therapeutic uses of berberine formulations
AU2017253935B2 (en) 2016-04-19 2021-07-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
US10675260B2 (en) 2017-01-19 2020-06-09 Twi Biotechnology, Inc. Methods and pharmaceutical compositions for preventing or treating immunoinflammatory dermal disorders
EP3398448A1 (en) 2017-05-05 2018-11-07 Vall Garraf, S.L. Fattening additive for animal nutritional composition
WO2019114705A1 (zh) 2017-12-13 2019-06-20 上海小午医药科技有限公司 一种用于预防或治疗与egfr被抑制相关疾病的方法
KR20200144116A (ko) 2018-04-16 2020-12-28 온퀄리티 파마슈티컬스 차이나 리미티드 암 치료의 부작용을 예방하거나 치료하기 위한 방법
SG11202010294RA (en) * 2018-04-18 2020-11-27 Forte Subsidiary Inc Compositions for the treatment of skin conditions
CN108329310A (zh) * 2018-05-07 2018-07-27 深圳市迪克曼科技开发有限公司 黄藤素的制备方法
SG11202011188SA (en) 2018-05-11 2020-12-30 Forte Subsidiary Inc Compositions for the treatment of skin conditions
CN110882246B (zh) * 2018-09-08 2022-12-23 西南大学 不同生物活性的黄连生物碱的提取方法及应用
JP2020045338A (ja) * 2018-09-12 2020-03-26 大正製薬株式会社 外用組成物
JP2022502489A (ja) 2018-09-25 2022-01-11 ポンス デ レオン ヘルス デジグネイテッド アクティビティ カンパニー αケトグルタル酸カルシウムを製造するためのプロセス
JP6535146B1 (ja) * 2019-03-08 2019-06-26 佐藤製薬株式会社 皮膚バリア機能改善剤
RU2697854C1 (ru) * 2019-05-14 2019-08-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ комбинированной наружной терапии эритематозно-папулезной розацеа

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150920A (ja) * 1984-08-20 1986-03-13 Ichimaru Fuarukosu Kk 黄柏抽出エキス含有液の製造法
JPS63179812A (ja) * 1987-01-22 1988-07-23 Shiseido Co Ltd 皮膚外用剤
JP2609564B2 (ja) * 1991-05-31 1997-05-14 政夫 斎藤 アレルギー性皮膚炎用クリーム及びその製造方法
CN1085600A (zh) * 1993-07-07 1994-04-20 南宁市迪生新技术研究所 防治性病、传染病的杀菌保健香皂和浴液
CN1182788A (zh) * 1997-02-03 1998-05-27 熊光明 一种防治性病传染病的保健洗涤用品
US6482839B1 (en) 1997-06-02 2002-11-19 Cellegy Pharmaceuticals, Inc. Pyridine-thiols for treatment of a follicular dermatosis
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
JP2001335485A (ja) * 2000-05-31 2001-12-04 Pola Chem Ind Inc メラノサイトのデンドライトの伸長抑制剤及びそれを含有する化粧料
KR20030082200A (ko) * 2002-04-17 2003-10-22 주식회사 엘지생활건강 베르베린을 함유하는 아토피성 피부염 예방 및 완화용조성물
US20040146539A1 (en) 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits
WO2004093876A2 (en) * 2003-04-03 2004-11-04 The Board Of Trustees Of The University Of Illinois Composition containing berberine or a derivative thereof and an antimicrobial agent or an antibiotic agent, and their use for treating oral pathogens and other disorders
US7205006B2 (en) * 2003-09-25 2007-04-17 Prime Pharmaceutical Corporation Mahonia aquifolium extract, extraction process and pharmaceutical composition containing the same
KR101045658B1 (ko) 2003-11-17 2011-07-01 쎄데르마 테트라펩티드 및 트리펩티드 혼합물을 포함하는 조성물
US20050158404A1 (en) 2003-11-18 2005-07-21 Goodless Dean R. Composition and method for treatment of acne
EP1591125A1 (de) * 2004-04-19 2005-11-02 Universitätsklinikum Freiburg Pharmazeutische Zusammensetzung enthaltend Extrakte aus Flechten und Johanniskraut
CA2612408A1 (en) * 2005-06-15 2006-12-28 Apollo Pharmaceutical, Inc. Pharmaceutical composition comprising a mahonia aquifolium extract for the treatment of psoriasis
CN100441183C (zh) * 2005-08-29 2008-12-10 中国医学科学院皮肤病研究所 盐酸13-己基小檗碱和盐酸13-己基巴马汀制备治疗湿疹、皮炎和银屑病的药物用途
DE202010004750U1 (de) * 2010-04-09 2011-10-11 Biofrontera Bioscience Gmbh Pharmazeutische oder/und kosmetische Zusammensetzung zur Behandlung der Haut

Also Published As

Publication number Publication date
KR20170116231A (ko) 2017-10-18
WO2011000218A1 (en) 2011-01-06
RU2671492C2 (ru) 2018-11-01
PL2448577T3 (pl) 2017-02-28
KR101699572B1 (ko) 2017-01-24
JP6159084B2 (ja) 2017-07-05
AU2010268647A1 (en) 2012-02-09
KR20170010442A (ko) 2017-01-31
NZ597645A (en) 2014-03-28
KR20120047240A (ko) 2012-05-11
CN102481290A (zh) 2012-05-30
ES2600909T3 (es) 2017-02-13
RU2014136492A (ru) 2016-03-27
RU2533458C2 (ru) 2014-11-20
RU2012102898A (ru) 2013-08-10
IL217264A0 (en) 2012-02-29
US9486402B2 (en) 2016-11-08
CA2766834C (en) 2017-04-25
US20120165357A1 (en) 2012-06-28
EP2448577B1 (en) 2016-09-14
EP2448577A4 (en) 2012-12-26
IL217264A (en) 2017-01-31
CA2766834A1 (en) 2011-01-06
MX344787B (es) 2017-01-05
AU2010268647B2 (en) 2015-01-15
CN105534978A (zh) 2016-05-04
JP2017082019A (ja) 2017-05-18
JP2012531448A (ja) 2012-12-10
HK1224206A1 (zh) 2017-08-18
MX2011014006A (es) 2012-06-12
EP2448577A1 (en) 2012-05-09

Similar Documents

Publication Publication Date Title
BRPI1012128A2 (pt) composições contendo berberina ou seus análogos para tratamento de rosácea ou distúrbios de pele relacionados com face vermelha.
BR112013015855A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
BR112014030414A2 (pt) combinação de um imunoconjugado, composição farmacêutica, uso de um imunoconjugado, métodos de tratamento e de estímulo, kit e invenção.
BR112014010179A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição
BRPI1013705A2 (pt) compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
BR112014010177A2 (pt) composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
BRPI0924425A2 (pt) "combinações de substâncias ativas sinergéticas".
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
BR112013015859A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica
BR112014013843A2 (pt) uso de dispositivos para o tratamento de doenças neurológicas
BR112012025961A2 (pt) composição farmacêutica oral, forma de dosagem de undecanoato de testosterona e método de tratar deficiência de testosterona ou seus sintomas
BR112014010164A2 (pt) implante de tecido duro
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
BR112012002265A2 (pt) composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios
BR112013001297A2 (pt) composições farmacêuticas e respectivo uso e método de tratamento de doença ou condição respiratória
BR112014029705A2 (pt) composto ou sal, medicamento, métodos para inibir quinase de janus em um mamífero, e para a profilaxia ou tratamento de doenças autoimunes, e, uso de um composto ou sal
BR112013015877A2 (pt) composto, uso de um composto, métodos de prevenção. tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
BRPI1009448A2 (pt) combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2626 DE 04-05-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.